5 High Growth Pharma Stocks that are Profitable

In this piece, we will take a look at five high growth pharma stocks that are profitable. For more stocks, head on over to 13 High Growth Pharma Stocks that are Profitable.

5. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Q/Q Sales Growth: 80%

Number of Hedge Fund Holders in Q3 2022: 21

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company that develops treatments for lymphoma, immune disorders, cancer, and leukemia. The firm is based in San Diego, California.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s third quarter of 2022 results saw the firm bring in $209 million in revenue, which marked a strong 80% annual growth. 21 of the 920 hedge funds polled by Insider Monkey during the same time period had also invested in the firm.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s largest investor in our database is Richard Driehaus’ Driehaus Capital which owns 1.3 million shares that are worth $76 million.

4. Vir Biotechnology, Inc. (NASDAQ:VIR)

Q/Q Sales Growth: 263%

Number of Hedge Fund Holders in Q3 2022: 18

Vir Biotechnology, Inc. (NASDAQ:VIR) develops several treatments for diseases such as the coronavirus, hepatitis, HIV, influenza, and other diseases. The firm is based in San Francisco, California.

Vir Biotechnology, Inc. (NASDAQ:VIR) earned $374.6 million in revenue for the three months that ended in September 2022. This enabled the firm to post a whopping 263% annual growth. Insider Monkey’s Q3 2022 survey covering 920 hedge funds revealed that 18 had invested in the company.

Vir Biotechnology, Inc. (NASDAQ:VIR)’s largest investor is Jim Simons’ Renaissance Technologies which owns 1 million shares that are worth $26 million.

3. Precigen, Inc. (NASDAQ:PGEN)

Q/Q Sales Growth: 406%

Number of Hedge Fund Holders in Q3 2022: 17

Precigen, Inc. (NASDAQ:PGEN) is a biotechnology firm that focuses on genetic and cellular therapies. These involve combining genetic components for genetic expression and a gene that improves immune system performance. The firm is headquartered in Germantown, Maryland.

Precigen, Inc. (NASDAQ:PGEN)’s third quarter results saw the firm post $13.4 million in revenue, which, when compared to the year ago quarter’s $3.3 million in sales marked a 406% annual growth. Insider Monkey surveyed 920 hedge funds for the September quarter of 2022 investments to discover that 17 had held a stake in Precigen, Inc. (NASDAQ:PGEN).

2. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Q/Q Sales Growth: 725%

Number of Hedge Fund Holders in Q3 2022: 13

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biotechnology firm that is developing products for diseases such as cardiovascular problems, arthritis, and skin issues. It is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is finally on an upward trajectory, as its third quarter of 2022 revenues stood at $92 million, accounting for a 725% annual growth. These revenues were also greater than the firm’s net sales for the first nine months of 2021. 13 of the 920 hedge funds part of Insider Monkey’s Q3 2022 survey of 920 hedge funds had invested in the firm.

Julian Baker and Felix Baker’s Baker Bros. Advisors is Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s largest shareholder. It owns 2.7 million shares that are worth $41 million.

1. SIGA Technologies, Inc. (NASDAQ:SIGA)

Q/Q Sales Growth: 1,400%

Number of Hedge Fund Holders in Q3 2022: 15

SIGA Technologies, Inc. (NASDAQ:SIGA) is a pharmaceutical company authorized to sell its products, which include a smallpox treatment, alongside others covering monkeypox and cowpox.

SIGA Technologies, Inc. (NASDAQ:SIGA) had a bumper third quarter of 2022 as its revenues stood at $72 million. When compared to the year ago quarter’s net sales of $4.8 million, this marked a stunning 1,400% annual growth. As of 2022’s third quarter, 15 of the 920 hedge funds polled by Insider Monkey had bought the firm’s shares.

SIGA Technologies, Inc. (NASDAQ:SIGA)’s largest hedge fund shareholder in our database is Touk Sinantha’s AltraVue Capital which owns 1.7 million shares that are worth $12 million.

Disclosure: None. You can also take a peek at 15 Biggest Insurance Companies in the World and 10 Best Performing Warren Buffett Stocks in 2023.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Follow Insider Monkey on Twitter